Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F21%3AA2202D37" target="_blank" >RIV/61988987:17110/21:A2202D37 - isvavai.cz</a>
Alternative codes found
RIV/00669806:_____/22:10436101 RIV/00843989:_____/22:E0109302 RIV/65269705:_____/22:00075975 RIV/00064173:_____/22:43922754 and 12 more
Result on the web
<a href="https://jitc.bmj.com/content/jitc/10/1/e003190.full.pdf" target="_blank" >https://jitc.bmj.com/content/jitc/10/1/e003190.full.pdf</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1136/jitc-2021-003190" target="_blank" >10.1136/jitc-2021-003190</a>
Alternative languages
Result language
angličtina
Original language name
Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial
Original language description
Background Most patients with epithelial ovarian cancer (EOC) relapse despite primary debulking surgery and chemotherapy (CT). Autologous dendritic cell immunotherapy (DCVAC) can present tumor antigens to elicit a durable immune response. We hypothesized that adding parallel or sequential DCVAC to CT stimulates antitumor immunity and improves clinical outcomes in patients with EOC. Based on the interim results of sequential DCVAC/OvCa administration and to accommodate the increased interest in maintenance treatment in EOC, the trial was amended by adding Part 2.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
JOURNAL FOR IMMUNOTHERAPY OF CANCER
ISSN
2051-1426
e-ISSN
—
Volume of the periodical
10
Issue of the periodical within the volume
1
Country of publishing house
GB - UNITED KINGDOM
Number of pages
11
Pages from-to
—
UT code for WoS article
000740755400004
EID of the result in the Scopus database
—